Health And Pharma

FDA Approves Durvalumab as First Perioperative Immunotherapy for Gastric and GEJ Cancers

Durvalumab (Imfinzi) combined with FLOT chemotherapy has been approved by the FDA as the first perioperative immunotherapy ...
Health And Pharma

FDA Approves Keytruda–Padcev Combination as First Perioperative Treatment for Bladder Cancer

The FDA has approved pembrolizumab (Keytruda) or pembrolizumab Qlex with enfortumab vedotin (Padcev) as the first ...
Health And Pharma

Sevabertinib Wins FDA Approval with Strong Responses in HER2-Mutated NSC Lung Cancer

The FDA has granted accelerated approval to sevabertinib (Hyrnuo), for previously treated HER+ metastatic non-squamous ...
Health And Pharma

FDA Approves Ziftomenib as First Targeted Therapy for (R or R) NPM1+ Acute Myeloid Leukemia

The FDA has approved ziftomenib (KOMZIFTI), the first oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). In the KOMET-001 trial, the therapy ...
healthandpharma

Novartis Invests $23 Billion to Boost Radioligand Manufacturing Capacity in Carlsbad

Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, marking another major step in its $23 billion U.S. expansion plan. The site, the ...
healthandpharma

ctDNA Blood Test Guides Chemotherapy Decisions for Tailored Colon Cancer Treatment

Findings from the DYNAMIC-III trial, show that ctDNA testing can transform post-surgical care in Stage III colon cancer. Among more than 1,000 patients, ctDNA-negative individuals achieved 87% ...
Health And Pharma

Ribociclib Extends Disease-Free Survival Beyond Treatment in HR+/HER2– Early Breast Cancer

Five-year data from the Phase III NATALEE trial confirm that adjuvant ribociclib (Kisqali) plus endocrine therapy reduces recurrence risk by 28% in patients with HR+/HER2– early breast cancer. The ...
healthandpharma

Lenvatinib Plus Pembrolizumab Delivers Durable 5-Year Survival in Endometrial Carcinoma

Five-year follow-up results from the Phase 3 Study 309/KEYNOTE-775, presented at ESMO 2025, confirm that lenvatinib plus pembrolizumab delivers a durable survival advantage over chemotherapy in ...
healthandpharma

Disarming Prostate Cancer: Dual Enzyme Blockade Weakens Tumors and Boosts Drug Response

A new PNAS study unveils a hidden vulnerability of prostate cancer: the protein-disulfide isomerases PDIA1 and PDIA5, which stabilize androgen receptor and sustain tumor survival. Inhibition of these ...
healthandpharma

LED-Activated SnOx Nanoflake Therapy Destroy Tumor Cells with Precision

Researchers from The University of Texas at Austin and the University of Porto have developed a groundbreaking LED-based cancer therapy using tin oxide (SnOx) nanoflakes that selectively destroy tumor ...
healthandpharma

In Vivo CAR T on the Horizon: BMS Acquires Orbital to Expand Cell Therapy Reach

Bristol Myers Squibb (BMS) has announced the acquisition of Orbital Therapeutics, a privately held biotech specializing in RNA-based immune reprogramming, in a $1.5 billion cash deal. The move ...
healthandpharma

The VAPOR 2 Trial and the Potential of Water Vapor Ablation in Prostate Cancer Treatment

Currently being evaluated in the pivotal VAPOR 2 clinical trial, the Vanquish system offers a minimally invasive approach that targets cancer with precision while preserving surrounding tissue. With ...